Supreet Kaur, MD

Novel Therapies in B cell lymphoma mainly Diffuse large B cell lymphoma, CLL and Primary CNS lymphoma

Associations

• Malignant Hematology
• Immuno-Oncology Program

My research focuses on improving outcomes in lymphoid malignancies through the integration of chemotherapy, immunotherapy, targeted agents, and cellular therapies. I am particularly interested in developing rational therapeutic combinations that enhance efficacy while minimizing toxicity. A central component of my work involves measurable residual disease (MRD)-guided clinical trials designed to personalize therapy intensity and reduce treatment-related morbidity without compromising disease control. In parallel, I am committed to advancing clinical trial design to improve diversity, equity, and access. Through innovative trial frameworks and the integration of technological tools, my goal is to ensure that study populations reflect the patients we serve in routine practice. This approach strengthens the generalizability of trial results and enhances their real-world applicability. I also conduct real-world outcomes research and incorporate patient-reported outcomes to better understand health-related quality of life, treatment tolerability, and both short- and long-term symptom burden associated with lymphoma and its therapies across the survivorship continuum.

Clinical Trial 23735
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
Condition: Malignant Hematology
Intervention: lisocabtagene maraleucel ()
Status: Open

Clinical Trial 24266
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Condition: Malignant Hematology
Intervention: ACP-196 (Acalabrutinib); Acalabrutinib (); GDC-0199 (Venetoclax); Sonrotoclax (); Venetoclax (); Zanubrutinib ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach A, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 Oct.391(15):1379-1389. Pubmedid: 39413375. Pmcid: PMC11488644.
• Bodor JN, Xiu J, Ernani V, Kaur S, Mamdani H, Ou SHI, Ma PC, Borghaei H, Clapper ML, VanderWalde A, Treat J. Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort. Clin Lung Cancer. 2024 Nov.25(7):e312-e315.e1. Pubmedid: 38811332. Pmcid: PMC11531605.
• Mines I, Al-Abayechi A, Kaur S, Nooruddin Z. Hyperviscosity Syndrome in Undifferentiated Connective Tissue Disease: A Diagnostic and Therapeutic Challenge. Cureus. 2024 Mar.16(3):e55399. Pubmedid: 38562334. Pmcid: PMC10984367.
• Roman Souza G, Nooruddin Z, Lee S, Boyle L, Lucero KT, Ananth S, Franklin K, Mader M, Toro Velez E, Naqvi A, Kaur S. The Impact of Time From Diagnosis to Initiation of Chemotherapy on Survival of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration. Clin Lymphoma Myeloma Leuk. 2024 Mar.24(3):e67-e77. Pubmedid: 38151390.
• West CV, Butler MJ, Kaur S, Bowhay-Carnes E, Karnad AB. Classical Hematology Referrals at an National Cancer Institute-Designated Cancer Center: Lessons Learned. JCO Oncol Pract. 2024 Jan.20(1):131-135. Pubmedid: 37713649.
• Ta A, Kaur S, Mader M, Franklin K, Williams M, Williams R, Blaize JP, Naqvi A, Ananth S, Song M, Warnecke BO, Pandya A, Djoumessi LRD, Nazarewicz P, Espinoza-Gutarra M, Lucero KT, Whitehead J, Al-Abayechi A, Boyle L, Lee S, Roman Souza G, Toro Velez E, Mines I, Nooruddin Z. The impact of race and ethnicity on diffuse large B-cell lymphoma outcomes within the veterans health administration (VHA). Leuk Lymphoma. 2024 Aug.65(8):1090-1099. Pubmedid: 38619488.
• Kaur S, Kollimuttathuillam S. Plasmablastic Lymphoma: Past, Present, and Future. Clin Lymphoma Myeloma Leuk. 2023 Sep.23(9):e253-e259. Pubmedid: 37453866.
• Tripathy S, Alvarez N, Jaiswal S, Williams R, Al-Khadimi M, Hackman S, Phillips W, Kaur S, Cervantez S, Kelly W, Taverna J. Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report. J Med Case Rep. 2022 Nov.16(1):445. Pubmedid: 36434709. Pmcid: PMC9700935.
• Kaur S, Bansal R, Kollimuttathuillam S, Gowda AM, Singh B, Mehta D, Maroules M. The looming storm: Blood and cytokines in COVID-19. Blood Rev. 2021 Mar.46:100743. Pubmedid: 32829962. Pmcid: PMC7431319.
• Singh B, Kaur P, Patel P, Reid RJ, Kumar A, Kaur S, Guragai N, Rushdy A, Bikkina M, Shamoon F. COVID-19 and Diabetic Ketoacidosis: A Single Center Experience. Cureus. 2021 Jan.13(1):e13000. Pubmedid: 33542884. Pmcid: PMC7847783.
• Kapoor A, Manje Gowda A, Kaur S, Estifan E, Maroules M. A Rare Case of Cerebral Amyloidoma Mimicking a Hemorrhagic Malignant Central Nervous System Neoplasm. Cureus. 2020 Mar.12(3):e7245. Pubmedid: 32284920. Pmcid: PMC7147526.
• Wu AH, Kaur S, Peng S, Kapoor A, Maroules M. A case of cervical spinal mass with cord compression and rib bone metastasis from presumably burned-out seminomatous testicular germ cell tumor. Can J Urol. 2019 Jun.26(3):9799-9801. Pubmedid: 31180313.
• Mehta D, Poojary P, Saha A, Kaur S, Patel S, Chawla L, Kumar A, Simoes P, Busayavalasa D, Nadkarni G, Sanaka M. National trends of endoscopic retrograde cholangiopancreatography utilization and outcomes in decompensated cirrhosis. Surg Endosc. 2019 Jan.33(1):169-178. Pubmedid: 29943059.
• Liu D, Mehta D, Kaur S, Kumar A, Parikh K, Chawla L, Patel S, Devi A, Saha A. Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective. J Hematol Oncol. 2018 Dec.11(1):138. Pubmedid: 30545376. Pmcid: PMC6293615.
• Kumar M, Kumar A, Kumar V, Kaur S, Maroules M. Hypercalcemia as Initial Presentation of Metastatic Adenocarcinoma of Gastric Origin: A Case Report and Review of the Literature. J Gastric Cancer. 2016 Sep.16(3):191-194. Pubmedid: 27752397. Pmcid: PMC5065949.
• Kaur S. Sinonasal Neuroendocrine Tumor With Head Lump and Seizures. Am J Med Sci. 2016 Oct.352(4):438. Pubmedid: 27776730.
• Kaur S, Kumar A, Lerner RG, Aronow WS. Reversal agents of non-vitamin K dependent anticoagulants: a rapid review of the changing horizon. Arch Med Sci. 2016 Oct.12(5):1174-1178. Pubmedid: 27695508. Pmcid: PMC5016595.